NCT01049061

A Study of MORAb-003 in Patients With Solid Tumor

A Phase 1 Study of MORAb-003 in Patients With Solid Tumor

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Eisai Co., Ltd. · Industry
• Sex: All
• Age: 20 Years – 79 Years
• Healthy volunteers: Not accepted

Summary

MORAb-003 is intravenously administered to Japanese patients with folate receptor-alpha expressing solid tumor once a week for 4 weeks as 1 cycle in order to investigate dose-limiting toxicity and estimate maximum tolerated dose.

Conditions

• Neoplasms
• Solid Tumor

Interventions

Type	Name	Description
DRUG	MORAb-003	MORAb-003 is intravenously administered to patients with solid tumor once a week for 4 weeks as 1 cycle in order to investigate dose-limiting toxicity and estimate maximum tolerated dose

Timeline

• Start date: 2010-01-01
• Primary completion: 2013-01-01
• Completion: 2013-02-01
• First posted: 2010-01-14
• Last updated: 2020-06-11

Locations

2 sites across 1 country: Japan